BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: A study of 44 Turkish patients

Cancer Genetics

Volumn 207, Issue 3, 2014, Pages 87-93

  Akay, Olga Meltem ^a   Aras, Beyhan Durak ^a   Isiksoy, Serap ^a   Toprak, Cigdem ^a   Mutlu, Fezan Sahin ^a   Artan, Sevilhan ^a   Oner, Ulku ^a   Gulbas, Zafer ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

BCL2; BCL6; Diffuse large B cell lymphoma; MYC; TP53

Indexed keywords

BETA 2 MICROGLOBULIN; LACTATE DEHYDROGENASE; MYC PROTEIN; PEPTIDES AND PROTEINS; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN IGH; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BCL2 GENE; BCL6 GENE; CANCER MORPHOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CELL HETEROGENEITY; CLINICAL ARTICLE; CYTOLOGY; ETHNIC GROUP; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FREQUENCY; GENE OVEREXPRESSION; GENE REARRANGEMENT; GLOBULIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IGH GENE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MALE; ONCOGENE; ONCOGENE MYC; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TP53 GENE; TURKISH;

BCL2; BCL6; DIFFUSE LARGE B-CELL LYMPHOMA; MYC; TP53;

APOPTOSIS REGULATORY PROTEINS; DNA-BINDING PROTEINS; GENE ORDER; GENES, MYC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TURKEY;

EID: 84899051152     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.02.001     Document Type: Article

References (45)

1. Rossi D., Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: Implications for disease management and prognosis. Hematology 2002, 7(4):239-252.
2. Sohn S.K., Jung J.T., Kim D.H., et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 2003, 73:101-107.
3. Chaganti R.S., Nanjangud G., Schmidt H., et al. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Semin Hematol 2000, 37:396-411.
4. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large B-cell lymphomas. NEngl J Med 2008, 359:2313-2323.
5. Shustik J., Han G., Farinha P., et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010, 95:96-101.
6. Mahmoud H.M., El-Sakhawy Y.N. Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma. Hematol Rep 2011, 3:e26.
7. Zhang A., Ohshima K., Sato K., et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int 1999, 49:1043-1052.
8. Lossos I.S., Jones C.D., Warnke R., et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001, 98:945-951.
9. De Paepe P., Achten R., Verhoef G., et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. JClin Oncol 2005, 23:7060-7068.
10. Tibiletti M.G., Martin V., Bernasconi B., et al. BCL2, BCL6, MYC, MALT1 and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 2009, 40:645-652.
11. van lmhoff G.W., Boerma E.L., van der Holt B., et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. JClin Oncol 2006, 24:4135-4142.
12. Kramer M.H., Hermans J., Wijburg E., et al. Clinical relevance of BCL2, BCL6 and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152-3162.
13. Colomo L., Lopez- Gullermo A., Perales M., et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003, 101:78-84.
14. Barrans S.L., Carter R.G., Owen R.G., et al. Germinal center phomotyphe and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B cell lymphoma. Blood 2002, 99:1136-1143.
15. Gascoyne R.D., Adomat S.A., Krajewski S., et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
16. Hermine O., Haioun C., Lepage E., et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkins's lymphoma: Groupe d'Etude des Lymphomes de I'Adulte (GELA). Blood 1996, 87:265-272.
17. Hill M.E., Maclennan K.A., Cunningham D.C., et al. Prognostic significance of BCL-2 expression and bcl-major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 1996, 88:1046-1051.
18. Barrans S.L., Evans P., O'Connor S., et al. The t(14;18) is associated with germinal center derived diffuse large B-cell lymphoma. Clin Cancer Res 2003, 9:2133-2139.
19. Tang S., Visser L., Hepperle B., et al. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases. JClin Oncol 1994, 12:149-154.
20. Vitolo U., Gaidano G., Botto B., et al. Rearrangements of bcl-6, bcl-2, c-myc, and 6q deletion in diffuse large cell lymphoma: clinical relevance in 71 patients. Ann Oncol 1998, 9:55-61.
21. Kawasaki C., Ohshim K., Suzumiya J., et al. Rearrangement of bcl-6, bcl-2, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma 2001, 42:1099-1106.
22. Yoon S.O., Jeon Y.K., Paik J.H., et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathol 2008, 53:205-217.
23. Hummel M., Bentink S., Berger H., et al. Abiologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. NEngl J Med 2006, 354:2419-2430.
24. Michael P. Growing importance of MYC/BCL2 immunochemistry in diffuse large B-cell lymhomas. JClin Oncol 2012, 30:3343-3435.
25. Koduru P.R., Raju K., Vadmal V., et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997, 90:4078-4091.
26. Jia Z., He J., Cen L., et al. P53 deletion is dependently associated with increased age and decreased survival in a cohort of Chinese patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2012, 53:2182-2185.
27. Sun G.X., Cao X.S., Li Q., et al. Correlation of BCL6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012, 29:576-581.
28. Chanq C.C., Liu Y.C., Cleveland R.P., et al. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 2000, 113:512-518.
29. Piris M.A., Pezella F., Martinez- Montero J.C., et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994, 69:337-341.
30. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed 2008, IARC Press, Lyon, France.
31. Jerkeman M., Anderson H., Dictor M., et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann Hematol 2004, 83:414-419.
32. Sweetenham J.W. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program 2005, 252-259.
33. Campbell L.J. Cytogenetics of lymphomas. Pathology 2005, 37:493-507.
34. Nedomova R., Papajik T., Prochazka V., et al. Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013, 157:239-247.
35. Monni O., Joensuu H., Franssila K., et al. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997, 90:1168-1174.
36. El-Hameed A.A. De novo nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors. JEgypt Natl Canc Inst 2005, 17:20-28.
37. Villuendas R., Piris M.A., Algara P., et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993, 82:3151-3156.
38. Offit K., Lo Coco F., Louie D.C., et al. Rearrangements of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. NEngl J Med 1994, 331:74-80.
39. Barrans S.L., Evans P., O'Connor S., et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002, 117:322-332.
40. Iqbal J., Greiner T.C., Patel K., et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007, 21:2332-2343.
41. Savage K.J., Johnson N.A., Ben-Neriah S., et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009, 114:3533-3537.
42. Barrans S., Crouch S., Smith A., et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. JClin Oncol 2010, 28:3360-3365.
43. Johnson N.A., Slack G.W., Savage K.J., et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. JClin Oncol 2012, 30:3460-3468.
44. Green T.M., Young K.H., Visco C., et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. JClin Oncol 2012, 30:3460-3467.
45. Stefancikova L., Moulis M., Fabian P., et al. Prognostic impact of p53 aberrations for R-CHOP-treated patients withdiffuse large B-cell lymphoma. Int J Oncol 2011, 39:1413-1420.